Genomic characterization of three urinary bladder cancer cell lines: understanding genomic types of urinary bladder cancer
详细信息 查看全文
- 作者：Rosário Pinto-Leite (1)
Isabel Carreira (2) (3)
Joana Melo (2) (3)
Susana Isabel Ferreira (2)
Ilda Ribeiro (2) (3)
Jaqueline Ferreira (1)
Marco Filipe (1)
Carina Bernardo (4)
Regina Arantes-Rodrigues (5)
Paula Oliveira (5)
Lúcio Santos (4) (6) (7) - 关键词：Urinary bladder cancer ; Urinary bladder cancer cell lines ; Genomic ; Chromosome ; aCGH ; MLPA
- 刊名：Tumor Biology
- 出版年：2014
- 出版时间：May 2014
- 年：2014
- 卷：35
- 期：5
- 页码：4599-4617
- 全文大小：
- 参考文献：1. Ismaili N, Amzerin M, Flechon A. Chemotherapy in advanced bladder cancer: current status and future. J Hematol Oncol. 2011;4:35. href="http://dx.doi.org/10.1186/1756-8722-4-35" target="_blank" title="It opens in new window">CrossRef
2. H?glund M. The bladder cancer genome; chromosomal changes as prognostic makers, opportunities, and obstacles. Urol Oncol. 2012;30(4):533-0. href="http://dx.doi.org/10.1016/j.urolonc.2012.04.001" target="_blank" title="It opens in new window">CrossRef
3. Escudero D, Shirodkar S, Lokeshwar V. Bladder carcinogenesis and molecular pathways. In: Lokeshwar VB, Merseburger AS, Hautmann SH, editors. Bladder tumours: molecular aspects and clinical management. Totowa: Humana; 2011. p. 29-2.
4. Hatina J, Huckenbeck W, Rieder H, Seifert HH, Schulz WA. Bladder carcinoma cell lines as models of the pathobiology of bladder cancer. Review of the literature and establishment of a new progression series. Urologe A. 2008;47(6):724-4.
5. Strefford JC, Lillington DM, Steggall M, Lane TM, Nouri AME, Young BD, et al. Novel chromosome findings in bladder-cancer cell lines detected with multiplex fluorescence in situ hybridization. Cancer Genet Cytogenet. 2002;135(2):139-6. href="http://dx.doi.org/10.1016/S0165-4608(01)00648-3" target="_blank" title="It opens in new window">CrossRef
6. Hurst CD, Fiegler H, Carr P, Williams S, Carter NP, Knowles MA. High-resolution analysis of genomic copy number alterations in bladder cancer by microarray-based comparative genomic hybridization. Oncogene. 2004;23(12):2250-3. href="http://dx.doi.org/10.1038/sj.onc.1207260" target="_blank" title="It opens in new window">CrossRef
7. Williams SV, Adams J, Coulter J, Summersgill BM, Shipley J, Knowles MA. Assessment by M-FISH of karyotypic complexity and cytogenetic evolution in bladder cancer in vitro. Genes Chromosomes Cancer. 2005;43(4):315-8. href="http://dx.doi.org/10.1002/gcc.20166" target="_blank" title="It opens in new window">CrossRef
8. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res. 2002;30(12):e57. href="http://dx.doi.org/10.1093/nar/gnf056" target="_blank" title="It opens in new window">CrossRef
9. Lindgren D, Liedberg F, Andersson A, Chebil G, Gudjonsson S, Borg A, et al. Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q. Oncogene. 2006;25(18):2685-6. href="http://dx.doi.org/10.1038/sj.onc.1209249" target="_blank" title="It opens in new window">CrossRef
10. Tanaka T, Miyazawa K, Tsukamoto T, Kuno T, Suzuki K. Pathobiology and chemoprevention of bladder cancer. J Oncol. 2011;2011:528353.
11. Netto GJ. Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet? Nat Rev Urol. 2011;9(1):41-1. href="http://dx.doi.org/10.1038/nrurol.2011.193" target="_blank" title="It opens in new window">CrossRef
12. Gallucci M, Guadagni F, Marzano R, Leonardo C, Merola R, Sentinelli S. Status of the p53, p16, RB1, and HER-2 genes and chromosomes 3, 7, 9, and 17 in advanced bladder cancer: correlation with adjacent mucosa and pathological parameters. J Clin Pathol. 2005;58(4):367-1. href="http://dx.doi.org/10.1136/jcp.2004.021154" target="_blank" title="It opens in new window">CrossRef
13. Mitra AP, Datar RH, Cote RJ. Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J Clin Oncol. 2006;24(35):5552-4. href="http://dx.doi.org/10.1200/JCO.2006.08.2073" target="_blank" title="It opens in new window">CrossRef
14. Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW, van der Kwast TH, Zwarthoff EC. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One. 2010;5(11):e13821. href="http://dx.doi.org/10.1371/journal.pone.0013821" target="_blank" title="It opens in new window">CrossRef
15. Lindgren D, Sj?dahl G, Lauss M, Staaf J, Chebil G, Lovgren K. Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma. PLoS One. 2012;7(6):e38863. href="http://dx.doi.org/10.1371/journal.pone.0038863" target="_blank" title="It opens in new window">CrossRef
16. Fujii T, Shimada K, Anai S, Fujimoto K, Konishi N. ALKBH2, a novel AlkB homologue, contributes to human bladder cancer progression by regulating MUC1 expression. Cancer Sci. 2013;104(3):321-. href="http://dx.doi.org/10.1111/cas.12089" target="_blank" title="It opens in new window">CrossRef
17. Ying L, Huang Y, Chen H, Wang Y, Xia L, Chen Y, et al. Downregulated MEG3 activates autophagy and increases cell proliferation in bladder cancer. Mol Biosyst. 2013;9(3):407-1. href="http://dx.doi.org/10.1039/c2mb25386k" target="_blank" title="It opens in new window">CrossRef
18. Ewald JA, Downs TM, Cetnar JP, Ricke WA. Expression microarray meta-analysis identifies genes associated with Ras/MAPK and related pathways in progression of muscle-invasive bladder transition cell carcinoma. PLoS One. 2013;8(2):e55414. href="http://dx.doi.org/10.1371/journal.pone.0055414" target="_blank" title="It opens in new window">CrossRef
19. Qi Y, Chang L, Li H, Yu G, Xiao W, Xia D, et al. Over-expression of LRIG3 suppresses growth and invasion of bladder cancer cells. J Huazhong Univ Sci Technolog Med Sci. 2013;33(1):111-. href="http://dx.doi.org/10.1007/s11596-013-1081-3" target="_blank" title="It opens in new window">CrossRef
20. Karkoulis PK, Stravopodis DJ, Konstantakou EG, Voutsinas GE. Targeted inhibition of heat shock protein 90 disrupts multiple oncogenic signaling pathways, thus inducing cell cycle arrest and programmed cell death in human urinary bladder-cancer cell lines. Cancer Cell Int. 2013;13(1):11. href="http://dx.doi.org/10.1186/1475-2867-13-11" target="_blank" title="It opens in new window">CrossRef
21. Pinto-Leite R, Arantes-Rodrigues R, Palmeira C, Gaiv?o I, Cardoso ML, Cola?o A, et al. Everolimus enhances gemcitabine-induced cytotoxicity in bladder-cancer cell lines. J Toxicol Environ Health A. 2012;75(13-5):788-9. href="http://dx.doi.org/10.1080/15287394.2012.690325" target="_blank" title="It opens in new window">CrossRef
22. Chiong E, Dadbin A, Harris LD, Sabichi AL, Grossman HB. The use of short tandem repeat profiling to characterize human bladder-cancer cell lines. J Urol. 2009;181(6):2737-8.
23. Masters JR. Cell-line authentication: end the scandal of false cell lines. Nature. 2012;492(7428):186. href="http://dx.doi.org/10.1038/492186a" target="_blank" title="It opens in new window">CrossRef
24. Vasconcelos-Nóbrega C, Pinto-Leite R, Arantes-Rodrigues R, Ferreira R, Brochado P, Cardoso ML, et al. In vivo and in vitro effects of RAD001 on bladder cancer. Urol Oncol. 2011;31(7):1212-1. href="http://dx.doi.org/10.1016/j.urolonc.2011.11.002" target="_blank" title="It opens in new window">CrossRef
25. Arantes-Rodrigues R, Pinto-Leite R, Ferreira R, Neuparth MJ, Pires MJ, Gaiv?o I, et al. Meloxicam in the treatment of in vitro and in vivo models of urinary bladder cancer. Biomed Pharmacother. 2013;67(4):277-4. href="http://dx.doi.org/10.1016/j.biopha.2013.01.010" target="_blank" title="It opens in new window">CrossRef
26. Shaffer LG, Slovak ML, Campbell LJ. ISCN: an International System for Human Cytogenetic Nomenclature: recommendations of the International Standing Committee on Human Cytogenetic Nomenclature. S. Karger. 2009.
27. Bruch J, Schulz WA, H?ussler J, Melzner I, Brüderlein S, Moller P, et al. Delineation of the 6p22 amplification unit in urinary bladder carcinoma cell lines. Cancer Res. 2000;60(16):4526-0.
28. Padilla-Nash HM, Heselmeyer-Haddad K, Wangsa D, Zhang H, Ghadimi BM, Macville M, et al. Jumping translocations are common in solid tumour cell lines and result in recurrent fusions of whole chromosome arms. Genes Chromosomes Cancer. 2001;30(4):349-3. href="http://dx.doi.org/10.1002/gcc.1101" target="_blank" title="It opens in new window">CrossRef
29. Fadl-Elmula I, Kyt?l? S, Pan Y, Lui WO, Derienzo G, Forsberg L. Characterization of chromosomal abnormalities in uroepithelial carcinomas by G-banding, spectral karyotyping and FISH analysis. Int J Cancer. 2001;92(6):824-1. href="http://dx.doi.org/10.1002/ijc.1267" target="_blank" title="It opens in new window">CrossRef
30. DSMZ. German collection of microorganisms and cell cultures. href="http://www.dsmz.de/" class="a-plus-plus">http://www.dsmz.de
31. Gildea JJ, Golden WL, Harding MA, Theodorescu D. Genetic and phenotypic changes associated with the acquisition of tumourigenicity in human bladder cancer. Genes Chromosomes Cancer. 2000;27(3):252-3. href="http://dx.doi.org/10.1002/(SICI)1098-2264(200003)27:3<252::AID-GCC5>3.0.CO;2-9" target="_blank" title="It opens in new window">CrossRef
32. Makridakis M, Gagos S, Petrolekas A, Roubelakis MG, Bitsika V, Stravodimos K. Chromosomal and proteome analysis of a new T24-based cell line model for aggressive bladder cancer. Proteomics. 2009;9(2):287-8. href="http://dx.doi.org/10.1002/pmic.200800121" target="_blank" title="It opens in new window">CrossRef
33. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-4. href="http://dx.doi.org/10.1016/j.cell.2011.02.013" target="_blank" title="It opens in new window">CrossRef
34. da Silva GN, Evangelista AF, Magalh?es DA, Macedo C, Búfalo MC, Sakamoto-Hojo ET, et al. Expression of genes related to apoptosis, cell cycle and signaling pathways are independent of TP53 status in urinary bladder cancer cells. Mol Biol Rep. 2011;38(6):4159-0. href="http://dx.doi.org/10.1007/s11033-010-0536-x" target="_blank" title="It opens in new window">CrossRef
35. Chekaluk Y, Wu CL, Rosenberg J, Riester M, Dai Q, Lin S. Identification of nine genomic regions of amplification in urothelial carcinoma, correlation with stage, and potential prognostic and therapeutic value. PLoS One. 2013;8(4):e60927. href="http://dx.doi.org/10.1371/journal.pone.0060927" target="_blank" title="It opens in new window">CrossRef
36. Elder PA, Bell SM, Knowles MA. Deletion of two regions on chromosome 4 in bladder carcinoma: definition of a critical 750kB region at 4p16.3. Oncogene. 1994;9(12):3433-6.
37. Tatarano S, Chiyomaru T, Kawakami K, Enokida H, Yoshino H, Hidaka H. miR-218 on the genomic loss region of chromosome 4p15.31 functions as a tumor suppressor in bladder cancer. Int J Oncol. 2011;39(1):13-1.
38. Richter J, Beffa L, Wagner U, Schraml P, Gasser TC, Moch H, et al. Patterns of chromosomal imbalances in advanced urinary bladder cancer detected by comparative genomic hybridization. Am J Pathol. 1998;153(5):1615-1. href="http://dx.doi.org/10.1016/S0002-9440(10)65750-1" target="_blank" title="It opens in new window">CrossRef
39. Perucca D, Szepetowski P, Simon MP, Gaudray P. Molecular genetics of human bladder carcinomas. Cancer Genet Cytogenet. 1990;49(2):143-6. href="http://dx.doi.org/10.1016/0165-4608(90)90136-X" target="_blank" title="It opens in new window">CrossRef
40. Knowles MA. What we could do now: molecular pathology of bladder cancer. Mol Pathol. 2001;54(4):215-1. href="http://dx.doi.org/10.1136/mp.54.4.215" target="_blank" title="It opens in new window">CrossRef
41. H?glund M, S?ll T, Heim S, Mitelman F, Mandahl N, Fadl-Elmula I. Identification of cytogenetic subgroups and karyotypic pathways in transitional cell carcinoma. Cancer Res. 2001;61(22):8241-.
42. Mitelman F, Johansson B, Mertens F. Mitelman database of chromosome aberrations in cancer. href="http://cgap.nci.nih.gov/Chromosomes/Mitelman" class="a-plus-plus">http://cgap.nci.nih.gov/Chromosomes/Mitelman. 2008; Accessed 25 January 2013.
43. Baffa R, Letko J, McClung C, LeNoir J, Vecchione A, Gomella G. Molecular genetics of bladder cancer: targets for diagnosis and therapy. J Exp Clin Cancer Res. 2006;25(2):145-0.
44. Forbes SA, Tang G, Bindal N, Bamford S, Dawson E, Cole C, et al. COSMIC (the catalogue of somatic mutations in cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res. 2010;38:D652-. href="http://dx.doi.org/10.1093/nar/gkp995" target="_blank" title="It opens in new window">CrossRef
45. Sanchez-Carbayo M, Socci ND, Charytonowicz E, Lu M, Prystowsky M, Childs G, et al. Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes. Cancer Res. 2002;62(23):6973-0.
46. Sheahan S, Bellamy CO, Dunbar DR, Harrison DJ, Prost S. Deficiency of G1 regulators P53, P21Cip1 and/or pRb decreases hepatocyte sensitivity to TGFbeta cell cycle arrest. BMC Cancer. 2007;7:215. href="http://dx.doi.org/10.1186/1471-2407-7-215" target="_blank" title="It opens in new window">CrossRef
47. Green DR, Kroemer G. Cytoplasmic functions of the tumour suppressor p53. Nature. 2009;458(7242):1127-0. href="http://dx.doi.org/10.1038/nature07986" target="_blank" title="It opens in new window">CrossRef
48. Foulkes WD, Flanders TY, Pollock PM, Hayward NK. The CDKN2A (p16) gene and human cancer. Mol Med. 1997;3(1):5-0.
49. Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szász AM, Wang ZC. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell. 2009;137(6):1032-6. href="http://dx.doi.org/10.1016/j.cell.2009.03.047" target="_blank" title="It opens in new window">CrossRef
50. Ivanov SV, Goparaju CM, Lopez P, Zavadil J, Toren-Haritan G, Rosenwald S, et al. Pro-tumorigenic effects of miR-31 loss in mesothelioma. J Biol Chem. 2010;285(30):22809-7. href="http://dx.doi.org/10.1074/jbc.M110.100354" target="_blank" title="It opens in new window">CrossRef
51. Di Benedetto M, Bièche I, Deshayes F, Vacher S, Nouet S, Collura V, et al. Structural organization and expression of human MTUS1, a candidate 8p22 tumor suppressor gene encoding a family of angiotensin II AT2 receptor-interacting proteins, ATIP. Gene. 2006;380(2):127-6. href="http://dx.doi.org/10.1016/j.gene.2006.05.021" target="_blank" title="It opens in new window">CrossRef
52. Wang T, Chen YH, Hong H, Zeng Y, Zhang J, Lu JP, et al. Increased nucleotide polymorphic changes in the 5-untranslated region of delta-catenin (CTNND2) gene in prostate cancer. Oncogene. 2009;28(4):555-4. href="http://dx.doi.org/10.1038/onc.2008.399" target="_blank" title="It opens in new window">CrossRef
53. Medeiros M, Zheng X, Novak P, Wnek SM, Chyan V, Escudero-Lourdes C, et al. Global gene expression changes in human urothelial cells exposed to low-level monomethylarsonous acid. Toxicology. 2012;291(1-):102-2. href="http://dx.doi.org/10.1016/j.tox.2011.11.002" target="_blank" title="It opens in new window">CrossRef
54. Safran M, Dalah I, Alexander J, Rosen N, Iny Stein T, Shmoish M, et al. GeneCards version 3: the human gene integrator. Database (Oxford). 2010;2010:baq020.
55. Mo L, Zheng X, Huang HY, Shapiro E, Lepor H, Cordon-Cardo, et al. Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumourigenesis. J Clin Invest. 2007;117(2):314-5. href="http://dx.doi.org/10.1172/JCI30062" target="_blank" title="It opens in new window">CrossRef
56. Blaveri E, Brewer JL, Roydasgupta R, Fridlyand J, DeVries S, Koppie T, et al. Bladder cancer stage and outcome by array-based comparative genomic hybridization. Clin Cancer Res. 2005;11(19 Pt 1):7012-2. href="http://dx.doi.org/10.1158/1078-0432.CCR-05-0177" target="_blank" title="It opens in new window">CrossRef
57. Wu XR. Urothelial tumourigenesis: a tale of divergent pathways. Nat Rev Cancer. 2005;5(9):713-5. href="http://dx.doi.org/10.1038/nrc1697" target="_blank" title="It opens in new window">CrossRef
58. Staub E, Gr?ne J, Mennerich D, R?pcke S, Klamann I, Hinzmann B, et al. A genome-wide map of aberrantly expressed chromosomal islands in colorectal cancer. Mol Cancer. 2006;5:37. href="http://dx.doi.org/10.1186/1476-4598-5-37" target="_blank" title="It opens in new window">CrossRef
59. Kanehisa M, Goto S, Sato Y, Furumichi M, Tanabe M. KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res. 2011;40:D109-4. href="http://dx.doi.org/10.1093/nar/gkr988" target="_blank" title="It opens in new window">CrossRef
60. Hurst CD, Tomlinson DC, Williams SV, Platt FM, Knowles MA. Inactivation of the Rb pathway and overexpression of both isoforms of E2F3 are obligate events in bladder tumours with 6p22 amplification. Oncogene. 2008;27(19):2716-7. href="http://dx.doi.org/10.1038/sj.onc.1210934" target="_blank" title="It opens in new window">CrossRef
61. Halling-Brown MD, Bulusu KC, Patel M, Tym JE, Al-Lazikani B. canSAR: an integrated cancer public translational research and drug discovery resource. Nucleic Acids Res. 2012;40:D947-6. href="http://dx.doi.org/10.1093/nar/gkr881" target="_blank" title="It opens in new window">CrossRef
62. Hoffmann R. A wiki for the life sciences where authorship matters. Nat Genet. 2008;40(9):1047-1. href="http://dx.doi.org/10.1038/ng.f.217" target="_blank" title="It opens in new window">CrossRef
63. Song T, Zhang X, Zhang L, Dong J, Cai W, Gao J, et al. miR-708 promotes the development of bladder carcinoma via direct repression of caspase-2. J Cancer Res Clin Oncol. 2013;139(7):1189-8. href="http://dx.doi.org/10.1007/s00432-013-1392-6" target="_blank" title="It opens in new window">CrossRef
64. Brait M, Munari E, Lebron C, Noordhuis MG, Begum S, Michailidi C, et al. Genome-wide methylation profiling and the PI3K-AKT pathway analysis associated with smoking in urothelial cell carcinoma. Cell Cycle. 2013;12(7):1058-0. href="http://dx.doi.org/10.4161/cc.24050" target="_blank" title="It opens in new window">CrossRef
65. Thompson PA, Brewster AM, Kim-Anh D, Baladandayuthapani V, Broom BM, Ederton E, et al. Selective genomic copy number imbalances and probability of recurrence in early-stage breast cancer. PLoS One. 2011;6(8):e23543. href="http://dx.doi.org/10.1371/journal.pone.0023543" target="_blank" title="It opens in new window">CrossRef
66. Orlando C, Sestini R, Vona G, Pinzani P, Bianchi S, Giacca M, et al. Detection of c-erbB-2 amplification in transitional cell bladder carcinoma using competitive PCR technique. J Urol. 1996;156(6):2089-3.
67. Hedrich CM, Crispin JC, Rauen T, Ioannidis C, Apostolidis SA, Lo MS, et al. cAMP response element modulator α controls IL2 and IL17A expression during CD4 lineage commitment and subset distribution in lupus. Proc Natl Acad Sci U S A. 2012;109(41):16606-1. href="http://dx.doi.org/10.1073/pnas.1210129109" target="_blank" title="It opens in new window">CrossRef
68. Rosenberg E, Baniel J, Spector Y, Faerman A, Meiri E. Predicting progression of bladder urothelial carcinoma using microRNA expression. BJU Int. 2013;112(7):1027-4.
69. Gregory SG, Barlow KF, McLay KE, Kaul R, Swarbreck D, Dunham A, et al. The DNA sequence and biological annotation of human chromosome 1. Nature. 2006;441(7091):315-1. href="http://dx.doi.org/10.1038/nature04727" target="_blank" title="It opens in new window">CrossRef - 作者单位：Rosário Pinto-Leite (1)
Isabel Carreira (2) (3)
Joana Melo (2) (3)
Susana Isabel Ferreira (2)
Ilda Ribeiro (2) (3)
Jaqueline Ferreira (1)
Marco Filipe (1)
Carina Bernardo (4)
Regina Arantes-Rodrigues (5)
Paula Oliveira (5)
Lúcio Santos (4) (6) (7)
1. Cytogenetic Laboratory, Department of Human Genetics, Hospital Center of Trás-os-Montes and Alto Douro, Vila Real, Portugal
2. Cytogenetics and Genomics Laboratory, Faculty of Medicine, University of Coimbra, Coimbra, Portugal
3. Center of Investigation on Environment Genetics and Oncobiology (CIMAGO), Faculty of Medicine, University of Coimbra, Coimbra, Portugal
4. Experimental Pathology and Therapeutics Group, Research Center, Portuguese Oncology Institute, Porto, Portugal
5. Centre for the Research and Technology of Agro-Environmental and Biological Sciences (CITAB), University of Trás-os-Montes and Alto Douro, Vila Real, Portugal
6. Department of Surgical Oncology, Portuguese Institute of Oncology, Porto, Portugal
7. Health Faculty, Fernando Pessoa University, Porto, Portugal - ISSN：1423-0380
文摘
Several genomic regions are frequently altered and associated with the type, stage and progression of urinary bladder cancer (UBC). We present the characterization of 5637, T24 and HT1376 UBC cell lines by karyotyping, fluorescence in situ hybridization (FISH), array comparative genomic hybridization (aCGH) and multiplex ligation-dependent probe amplification (MLPA) analysis. Some cytogenetic anomalies present in UBC were found in the three cell lines, such as chromosome 20 aneuploidy and the loss of 9p21. Some gene loci losses (e.g. CDKN2A) and gains (e.g. HRAS, BCL2L1 and PTPN1) were coincident across all cell lines. Although some significant heterogeneity and complexity were detected between them, their genomic profiles exhibited a similar pattern to UBC. We suggest that 5637 and HT1376 represent the E2F3/RB1 pathway due to amplification of 6p22.3, concomitant with loss of one copy of RB1 and mutation of the remaining copy. The HT1376 presented a 10q deletion involving PTEN region and no alteration of PIK3CA region which, in combination with the inactivation of TP53, bears more invasive and metastatic properties than 5637. The T24 belongs to the alternative pathway of FGFR3/CCND1 by presenting mutated HRAS and over-represented CCND1. These cell lines cover the more frequent subtypes of UBC and are reliable models that can be used, as a group, in preclinical studies.